Immunic to participate in investor and scientific conferences in november and december

New york , nov. 10, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in november and december: november 17: immunic's multiple sclerosis r&d webcast. immunic's management will be joined by renowned key opinion leaders to discuss the unmet medical need and recent scientific findings in the multiple sclerosis space as well as to provide an update on the development progress of lead asset, vidofludimus calcium (imu-838), in multiple sclerosis in a webcast on thursday, november 17, 2022 at 11:00 am et.
IMUX Ratings Summary
IMUX Quant Ranking